Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Capricor Therapeutics, Inc. CAPR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
64/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$47.75
+37.5%

Capricor Therapeutics, Inc. (CAPR) is a Biotechnology company in the Healthcare sector, currently trading at $34.72. It has a SharesGrow Score of 62/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is CAPR = $48 (+37.5% upside).

Valuation: CAPR trades at a trailing Price-to-Earnings (P/E) of -14.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.

Net income is $105M (loss), growing at -72.6%/yr. Net profit margin is 0% (thin). Gross margin is 93.6% (+20.8 pp trend).

Balance sheet: total debt is $21M against $306M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 9.01 (strong liquidity). Debt-to-assets is 5.9%. Total assets: $356M.

Analyst outlook: 10 / 10 analysts rate CAPR as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 97/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 62/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

$47.75
▲ 37.53% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Capricor Therapeutics, Inc., the average price target is $47.75, with a high forecast of $62.00, and a low forecast of $13.00.
Highest Price Target
$62.00
Average Price Target
$47.75
Lowest Price Target
$13.00

CAPR SharesGrow Score Overview

77/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 97/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CAPR

✓
VALUE Pass
97/100
CAPR trades at a trailing Price-to-Earnings (P/E) of -14.6 (S&P 500 average ~25). Forward PEG 0.07 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.57. Analyst consensus target is $48, implying +38.2% from the current price $35. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
CAPR: +258.5%/yr revenue is, -72.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet CAPR: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 9.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
CAPR: Gross margin is 93.6% (+20.8 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 10 / 10 analysts rate CAPR as buy (100%). Analyst consensus target is $48 (+38.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.3-40.37
Volume930.76K
Avg Volume (30D)1.33M
Market Cap$1.59B
Beta (1Y)0.48
Share Statistics
EPS (TTM)-2.26
Shares Outstanding$46.48M
IPO Date2007-02-13
Employees160
CEOLinda Marbán
Financial Highlights & Ratios
EBITDA$-108.14M
Net Income$-105.04M
Operating Income$-108.14M
Total Cash$318.13M
Total Debt$20.94M
Net Debt$-266.9M
Total Assets$355.95M
Price / Earnings (P/E)-15.4
Analyst Forecast
1Y Price Target$50.00
Target High$62.00
Target Low$13.00
Upside+44.0%
Rating ConsensusBuy
Analysts Covering10
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS14070B3096

Price Chart

Track all markets on TradingView
CAPR
Capricor Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
4.30 52WK RANGE 40.37

People Also View

CDTX
CDTX
Cidara Therapeutics, Inc.
$221.38
+0.00%
 IDYA
IDYA
IDEAYA Biosciences, Inc.
$32.35
-1.43%
 SLNO
SLNO
Soleno Therapeutics, Inc.
$52.62
-0.04%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MGTX
MGTX
MeiraGTx Holdings plc
$11.29
+17.24%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 KROS
KROS
Keros Therapeutics, Inc.
$11.55
+3.59%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.94
+4.83%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message